Home

 
 
 
 
 
 
 
 
 
CNN

WOLF BLITZER

Travel
CHINA
Cambodia
Dr. Beat Richner
Thailand
Phnom Penh
Angkor Wat
Consumer Reports
Thai Police Harass

Sheldon Adelson

SPORTS
JUNIOR SEAU
ELGIN BAYLOR
BILL RUSSELL
BOB PETTIT

 

 

 

 

 

 

 

 

 

 

 

 

 

CNN'S FAKE NEWS

 

 

 

 

BUSINESS - Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

 

 

 

 

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine - Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses - The booster dose elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), and the Beta and Delta variants, compared to the levels observed after the two-dose primary series - After the booster dose, neutralizing titers for variants were similar to wild type - Given the high levels of immune responses observed, a booster dose given within 6 to 12 months after the primary vaccination schedule may help maintain a high level of protection against COVID-19

 

NEW YORK, USA & MAINZ, Germany --- (BUSINESS WIRE)

Tuesday August 17, 2021

Pfizer Inc.and BioNTech SE announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.

“Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. Still, with the continuing threat of the Delta variant and possible emergence of other variants in the future, we must remain vigilant against this highly contagious virus,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule. We are pleased to submit these data to the FDA as we continue working together to address the evolving challenges of this pandemic.”

“We continuously strive to stay at least one step ahead of the virus. This is why we aim to expand access to our vaccine for people around the world and are working on various approaches as part of our comprehensive strategy to address the virus and its variants today as well as in the future,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “This initial data indicate that we may preserve and even exceed the high levels of protection against the wild-type virus and relevant variants using a third dose of our vaccine. A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season.”

Pfizer and BioNTech have submitted Phase 1 data – part of their Phase 1/2/3 clinical trial program – evaluating the safety, tolerability, and immunogenicity of a third dose of the COVID-19 vaccine in U.S. adult participants from the Phase 1 trial of the two-dose series. Participants received a 30-µg booster dose of BNT162b2 8 to 9 months after receiving the second dose. Results from this participant group show that the third dose elicited significantly higher neutralizing antibodies against the initial SARS-CoV-2 virus (wild type) compared to the levels observed after the two-dose primary series, as well as against the Beta variant and the highly infectious Delta variant.

Phase 3 results evaluating the third dose are expected shortly and will be submitted to the FDA, the EMA and other regulatory authorities worldwide. In the U.S., Pfizer and BioNTech plan to seek licensure of the third dose via a supplemental Biologics License Application (BLA) in individuals 16 years of age and older, pending FDA approval of the primary BLA submitted in May 2021.

A third dose of the Pfizer-BioNTech vaccine is not currently authorized for broad use in the U.S. However, under the current amended Emergency Use Authorization, a third dose was authorized on August 12 for administration to individuals at least 12 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization is based on information from an independent report evaluating safety and effectiveness of a third dose in people who received solid organ transplants.

© Copyright: National Radio. Any use of these materials, whole or in part, is prohibited unless authorized in writing by National Radio. Contact: nationalradio@yahoo.com All rights reserved.

 

NBA

 

Los Angeles Lakers
NBA MAX French language
Kyrie Irving
LeBron's Castoffs Excel
Giannis Antetokounmpo
KEVIN DURANT
LAKERS BUSTED
KOBE BRYANT

 

SPORTS

 

THE NHL's HULLS

 

NFL

 

Tom Brady's Bunch
Christian McCAFFREY

Super Bowl Pioneers

 

MLB

 

Shoehei Ohtani

Mike Piazza

 

SOCCER

 

FIFA Top 10

LUIS SUAREZ
FIFA News
Sepp BLATTER MATTER?

 

TENNIS

 

Emma Raducanu

Williams Family
Joe Frazier

RONDA ROUSEY

TIGER WOODS